MetaCap

Capricor Therapeutics (CAPR) vs DiaMedica Therapeutics (DMAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 32.0% versus a gain of 8.1%. Over five years, CAPR leads with a +122.6% price change compared with +118.8% for DMAC. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $441.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%DMAC+8.13%
+542%+241%-60%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%DMAC+115.97%
+1011%+444%-122%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus DMAC key metrics
MetricCAPRDMAC
Share price$7.59$8.25
Market cap$441.30M$445.15M
1-day change+0.80%+2.87%
YTD return-73.70%+3.64%
1-year return+32.00%+8.13%
5-year return+122.58%+118.83%
EPS (TTM)$-2.65$-0.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-105.04M$-32.77M
52-week high$40.37$11.00
52-week low$2.96$5.25
Distance from 52-week high-81.20%-25.00%
Analyst consensusbuystrong_buy
Avg. price target upside+259.03%+96.97%
Average volume4.73M210.46K
Shares outstanding58.14M53.96M
Employees23135
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed DMAC by 23.9 percentage points over the past year.

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

CAPR vs DMAC FAQ

Which is bigger, Capricor Therapeutics or DiaMedica Therapeutics?

DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $441.30M for Capricor Therapeutics (CAPR).

Which stock has performed better over the past year, CAPR or DMAC?

CAPR returned +32.00% over the past 12 months, compared with +8.13% for DMAC (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and DiaMedica Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons